75 related articles for article (PubMed ID: 27897918)
1. Pain is not associated with worse office-based buprenorphine treatment outcomes.
Fox AD; Sohler NL; Starrels JL; Ning Y; Giovanniello A; Cunningham CO
Subst Abus; 2012; 33(4):361-5. PubMed ID: 22989279
[TBL] [Abstract][Full Text] [Related]
2. Predictors of outcome after short-term stabilization with buprenorphine.
Hillhouse M; Canamar CP; Ling W
J Subst Abuse Treat; 2013 Mar; 44(3):336-42. PubMed ID: 23021099
[TBL] [Abstract][Full Text] [Related]
3. Implementing group visits for opioid use disorder: A case series.
Sokol R; Albanese M; Albanese C; Coste G; Grossman E; Morrill D; Roll D; Sobieszczyk A; Schuman-Olivier Z
Subst Abus; 2020; 41(2):174-180. PubMed ID: 31418638
[No Abstract] [Full Text] [Related]
4. "I'm on the Right Path": Exploring 1-Month Retention in a Homeless-Tailored Outpatient-Based Opioid Treatment Program.
Fine DR; Critchley N; Hart K; Joyce A; Sporn N; Gaeta J; Wright J; Baggett TP; Kruse G
Subst Use Addctn J; 2024 Apr; 45(2):268-277. PubMed ID: 38258838
[TBL] [Abstract][Full Text] [Related]
5. Buprenorphine treatment outcomes among opioid-dependent cocaine users and non-users.
Cunningham CO; Giovanniello A; Kunins HV; Roose RJ; Fox AD; Sohler NL
Am J Addict; 2013; 22(4):352-7. PubMed ID: 23795874
[TBL] [Abstract][Full Text] [Related]
6. The effectiveness of substance use interventions for homeless and vulnerably housed persons: A systematic review of systematic reviews on supervised consumption facilities, managed alcohol programs, and pharmacological agents for opioid use disorder.
Magwood O; Salvalaggio G; Beder M; Kendall C; Kpade V; Daghmach W; Habonimana G; Marshall Z; Snyder E; O'Shea T; Lennox R; Hsu H; Tugwell P; Pottie K
PLoS One; 2020; 15(1):e0227298. PubMed ID: 31945092
[TBL] [Abstract][Full Text] [Related]
7. Implementation of a medical student-run telemedicine program for medications for opioid use disorder during the COVID-19 pandemic.
Castillo M; Conte B; Hinkes S; Mathew M; Na CJ; Norindr A; Serota DP; Forrest DW; Deshpande AR; Bartholomew TS; Tookes HE
Harm Reduct J; 2020 Nov; 17(1):88. PubMed ID: 33203460
[TBL] [Abstract][Full Text] [Related]
8. Health-related quality of life changes associated with buprenorphine treatment for opioid dependence.
Raisch DW; Campbell HM; Garnand DA; Jones MA; Sather MR; Naik R; Ling W
Qual Life Res; 2012 Sep; 21(7):1177-83. PubMed ID: 21987030
[TBL] [Abstract][Full Text] [Related]
9. Overlapping buprenorphine, opioid, and benzodiazepine prescriptions among veterans dually enrolled in Department of Veterans Affairs and Medicare Part D.
Gellad WF; Zhao X; Thorpe CT; Thorpe JM; Sileanu FE; Cashy JP; Mor M; Hale JA; Radomski T; Hausmann LR; Fine MJ; Good CB
Subst Abus; 2017; 38(1):22-25. PubMed ID: 27925868
[TBL] [Abstract][Full Text] [Related]
10. Comparison of abuse, suspected suicidal intent, and fatalities related to the 7-day buprenorphine transdermal patch versus other opioid analgesics in the National Poison Data System.
Coplan PM; Sessler NE; Harikrishnan V; Singh R; Perkel C
Postgrad Med; 2017 Jan; 129(1):55-61. PubMed ID: 27922764
[TBL] [Abstract][Full Text] [Related]
11. Distinctive Trajectories of Opioid Use Over an Extended Follow-up of Patients in a Multisite Trial on Buprenorphine + Naloxone and Methadone.
Hser YI; Huang D; Saxon AJ; Woody G; Moskowitz AL; Matthews AG; Ling W
J Addict Med; 2017; 11(1):63-69. PubMed ID: 27898496
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Tolerability of Co-Administering Full µ-Opioid Receptor Agonists with Buprenorphine and Mixed Opioid Agonists.
Ruan X; Luo J; Kaye AD
Drug Res (Stuttg); 2017 Mar; 67(3):189-190. PubMed ID: 27926949
[No Abstract] [Full Text] [Related]
13. Primary Care-Based Models for the Treatment of Opioid Use Disorder: A Scoping Review.
Korthuis PT; McCarty D; Weimer M; Bougatsos C; Blazina I; Zakher B; Grusing S; Devine B; Chou R
Ann Intern Med; 2017 Feb; 166(4):268-278. PubMed ID: 27919103
[TBL] [Abstract][Full Text] [Related]
14. PROTOCOL: A comprehensive review of prioritized interventions to improve the health and wellbeing of persons with lived experience of homelessness.
Pottie K; Mathew CM; Mendonca O; Magwood O; Saad A; Abdalla T; Stergiopoulos V; Bloch G; Brcic V; Andermann A; Aubry T; Ponka D; Kendall C; Salvalaggio G; Mott S; Kpade V; Lalonde C; Hannigan T; Shoemaker E; Mayhew AD; Thavorn K; Tugwell P
Campbell Syst Rev; 2019 Sep; 15(3):e1048. PubMed ID: 37133294
[No Abstract] [Full Text] [Related]
15. Adaptation of the Tele-Harm Reduction intervention to promote initiation and retention in buprenorphine treatment among people who inject drugs: a retrospective cohort study.
Suarez E; Bartholomew TS; Plesons M; Ciraldo K; Ostrer L; Serota DP; Chueng TA; Frederick M; Onugha J; Tookes HE
Ann Med; 2023 Dec; 55(1):733-743. PubMed ID: 36856571
[No Abstract] [Full Text] [Related]
16. Opioid use disorder treatment for people experiencing homelessness: A scoping review.
McLaughlin MF; Li R; Carrero ND; Bain PA; Chatterjee A
Drug Alcohol Depend; 2021 Jul; 224():108717. PubMed ID: 33985863
[TBL] [Abstract][Full Text] [Related]
17. A crack in the wall: Chronic pain management in integrative group medical visits.
Thompson-Lastad A; Rubin S
Soc Sci Med; 2020 Aug; 258():113061. PubMed ID: 32497824
[TBL] [Abstract][Full Text] [Related]
18. Retention of Patients With Multiple Vulnerabilities in a Federally Qualified Health Center Buprenorphine Program: Pennsylvania, 2017-2018.
Weinstein LC; Iqbal Q; Cunningham A; Debates R; Landistratis G; Doggett P; Silverio A
Am J Public Health; 2020 Apr; 110(4):580-586. PubMed ID: 32078355
[No Abstract] [Full Text] [Related]
19. Buprenorphine shared medical appointments for the treatment of opioid dependence in a homeless clinic.
Doorley SL; Ho CJ; Echeverria E; Preston C; Ngo H; Kamal A; Cunningham CO
Subst Abus; 2017; 38(1):26-30. PubMed ID: 27897918
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
